Ranbaxy and Teva announce generic Lipitor agreement

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited ("Ranbaxy"), a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva.

Atorvastatin Calcium Tablets are the generic version of Pfizer's Lipitor® Tablets. Annual sales of Lipitor® were approximately $7.8 billion in the United States as of September 2011, based on IMS sales data.

Source:

Teva Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
High-performing age-stratified machine-learning models for the prediction of the severity of COVID-19 progression